DexCom (DXCM) Q2 Revenue Jumps 15%
(NASDAQ:DXCM) reported its second-quarter 2025 results on July 30, 2025, delivering an upbeat performance highlighted by a revenue beat and continued expansion in the key type 2 diabetes market. The maker of continuous glucose monitoring (CGM) systems posted GAAP revenue of $1.16 billion, above the analyst estimate of $1.12 billion, and Non-GAAP earnings per share (EPS) of $0.48 versus the $0.44 consensus. Despite the margin headwinds from elevated freight and supply chain costs, the quarter reflected ongoing success in launching new features and growing its user base. Management raised its full-year revenue outlook, signaling confidence in strong demand for the remainder of fiscal 2025.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
DexCom develops and sells continuous glucose monitoring (CGM) systems, which help people with diabetes track their blood sugar levels in real time. Its flagship products include the DexCom G6 and G7 sensor platforms as well as the Stelo, an over-the-counter CGM device. These tools eliminate the need for traditional finger stick testing and support better diabetes management through frequent, automated readings delivered to smartphones and other devices.
Source Fool.com
Dexcom Inc. Aktie
Hohe Buy- und niedrige Sell-Zahlen bei Dexcom Inc. zeigen ein stark positives Sentiment.
Für Dexcom Inc. ergibt sich ein Potenzial von -4.82%, selbst wenn das Kursziel von 75 € unter dem aktuellen Kurs von 78.8 € liegt.
